Edwards' PASCAL System Improves Outcomes And Quality Of Life In Tricuspid Valve Disease Trial

What happened

Edwards Lifesciences reported positive CLASP II TR trial results. After one year, 80% of patients treated with its PASCAL valve repair system had moderate or less severe tricuspid regurgitation, compared with 30% on medical therapy alone. Patients also reported an 18-point quality-of-life improvement.

Confirmed

Global impact / market context

If regulators and doctors accept these results, Edwards could sell more PASCAL devices, lifting revenue and profit per sale. Wider use would also shift treatment away from pills alone toward a one-time procedure, changing how hospitals budget for heart valve care.

Analyst inference

Edwards already sells heart devices in a competitive field where rival makers pursue similar valve repairs. Strong trial data can support investor expectations for future sales growth, but actual revenue depends on doctor adoption, insurance coverage, and hospital spending on new procedures.

Analyst inference

What to watch

1. Edwards said the PASCAL system received FDA approval for tricuspid valve repair in October 2026 and has already treated thousands of patients worldwide, which means US regulators cleared it for this use. Confirmed
2. Watch whether Edwards files these trial results with regulators in other countries to expand approval beyond the US, since wider clearance would allow more hospitals to offer the procedure. Proposed
3. Track hospital adoption and insurance coverage decisions, because if payers reimburse the procedure, device orders and Edwards revenue could rise; slow coverage would limit sales growth despite good trial data. Analyst inference

Evidence

• Original source link unavailable